Cambridge Healthtech Institute’s 22nd Annual
Recombinant Protein Expression and Production
Enhancing Expression, Performance, and Process
January 21-22, 2020
Part of the Biotherapeutic Expression & Production pipeline
Great strides have been made in the expression, production, and purification of biotherapeutics. However, hurdles remain to improving the quantity and quality of the efficient expression and production of these valuable biomolecules while minimizing time and cost. There is a greater demand for higher-throughput expression and purification, as well as more flexible expression platforms. Unfortunately, there is no “universal” production system which can guarantee high yields of recombinant protein, particularly as every biomolecule causes issues in terms of its own expression. Cambridge Healthtech Institute’s 22nd Annual Recombinant Protein Expression and Production conference explores the newest data and innovations relating to the best choices in hosts/systems, as well as ways to “rescue” existing systems and make them work more effectively to produce the quality and quantity of the desired biotherapeutic.
FEATURED PRESENTATION: Analysis of the Immunoglobulin G (IgG) Secretion Efficiency in Recombinant Chinese Hamster Ovary (CHO) Cells by using Citrine-Fusion IgG
Takeshi Omasa, PhD, Professor, Department of Material and Life Science, Graduate School of Engineering, Osaka University
Novel Prediction Tool to Evaluate Synonymous Changes in Recombinant Therapeutic Proteins
Nobuko Katagiri, PhD, Research Biologist, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, CBER, FDA
Recombinant Protein Production in Research at Novo Nordisk
Brian Vandahl, PhD, Corporate Vice President, Recombinant Technologies, Global Research Technologies, Novo Nordisk A/S
Recent Advances in Screening and Production of Recombinant Proteins in Plants and Plant Cells
Johannes Buyel, Dr-Ing, Head, Integrated Production Platforms, Fraunhofer Institute for Molecular Biology and Applied Ecology IME
Attenuated Glutamine Synthetase as a Selection Marker in CHO Cells to Efficiently Isolate Highly Productive Stable Cells for the Production of Antibodies and Other Biologics
Zhiwei Song, PhD, Principal Scientist & Lead Principal Investigator, Expression Engineering, Bioprocessing Technology Institute, A*STAR
Antibody Production Using an Inducible CHO Cell Line: Process Development and Intensification
Olivier Henry, PhD, Associate Professor, Chemical Engineering, Polytechnique Montréal
Engineering Cells for Heparin and Heparan Sulfate Production
Charles A. Glass, PhD, President & CSO, TEGA Therapeutics, Inc.
Scalable Production and Purification of Single-Stranded DNA
Tyson Shepherd, Research Associate, Mark Bathe Laboratory, Department of Biological Engineering, Massachusetts Institute of Technology
* The program is subject to change without notice, due to unforeseen reason.
2020 Conferences & Training Seminars